Overview

Two leading experts in type 2 diabetes management will review the benefits and limitations of GLP-1 receptor agonists, including a new oral agent in this class, by providing expert syntheses of clinical trial data and demonstrating how to turn this information into useful, actionable guidance for routine patient care. 

Learning Objectives

  • Differentiate GLP-1 RAs from the DPP-4 inhibitors, beyond the route of administration
  • Explain the rationale for the prioritization of the GLP-1 RA medication class in the management of patients with T2DM
  • Summarize the results of cardiovascular outcomes trials for current and emerging GLP-1 RAs, as data are available
  • Counsel patients with T2DM about agent-specific characteristics of current and emerging GLP-1 RAs 

Faculty

John E. Anderson, MD

Past President
The Frist Clinic
Nashville, TN 

Deborah Hinnen, APN, BC-ADM, CDE, FAAN, FAADE

Advanced Practice Nurse and Certified Diabetes Educator
University of Colorado Health
Colorado Springs, CO
Adjunct Professor
Department of Graduate Nursing
Wichita State University
Wichita, KS 

Disclosures

The following relevant financial relationships have been disclosed by faculty: 

John E. Anderson, MD  

Advisory Board for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; Lilly USA, LLC; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk Inc.; and Sanofi US. Consultant for AstraZeneca; Janssen Scientific Affairs, LLC; Lilly USA, LLC; Novo Nordisk Inc.; and Sanofi US. Speaker's Bureau for AstraZeneca; Janssen Scientific Affairs, LLC; Lilly USA, LLC; Novo Nordisk Inc.; and Sanofi US. 

Deborah Hinnen, APN, BC-ADM, CDE, FAAN, FAADE

Advisory Board for Janssen Scientific Affairs, LLC; Lilly USA, LLC; Merck & Co., Inc.; Novo Nordisk Inc.; and Sanofi US. Speaker's Bureau for Janssen Scientific Affairs, LLC; Lilly USA, LLC; Novo Nordisk Inc.; and Sanofi US.

 

Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships. 


CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement

pmiCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

pmiCME is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.


Designation Statement

This program has been approved for 0.74 contact hour of continuing education, which includes 0.41 hour of pharmacology.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 4 out of the 5 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge & Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 


Commercial Supporter

Novo Nordisk Inc.

Education Partner

PeerView Institute for Medical Education


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.